The New York Times, December 19, 2021 (with Andrew Jacobs)

Link

First identified in Botswana and South Africa in November, the Omicron variant has surged around the world over the past few weeks, faster than any previously known form of the coronavirus. While there’s a lot that scientists have yet to understand about Omicron, what they know already makes it clear that the variant could cause a huge number of new cases and that it could push some hospital systems to the breaking point.

Scientists first recognized Omicron thanks to its distinctive combination of more than 50 mutations. Some of them were carried by earlier variants such as Alpha and Beta, and previous experiments had demonstrated that they could enable a coronavirus to spread quickly. Other mutations were known to help coronaviruses evade antibodies produced by vaccines.

Continue reading “This is what researchers know about how Omicron works.”

The New York Times, December 15, 2021 (with Sheryl Stolberg)

Link

A flurry of new laboratory studies indicate that vaccines, and especially booster shots, may offer protection against the worst outcomes from the fast-spreading Omicron coronavirus variant. The highly mutated virus, however, will still cause many breakthrough infections in vaccinated people and in those who have been infected with older versions of the virus, according to the research.

At a World Health Organization meeting on Wednesday, scientists reported on several studies suggesting that T cells in vaccinated people can put up a strong defense against the variant, which could help prevent severe disease, hospitalization and death.

Continue reading “New Studies Raise Hopes That Vaccines Prevent Severe Disease From Omicron”

The New York Times, December 15, 2021

Link

At a World Health Organization meeting on Wednesday, scientists offered some encouraging findings about immunity against the fast-spreading Omicron variant of the coronavirus. Several laboratory studies suggest that so-called T cells in vaccinated people can put up a strong defense against the variant, which could help prevent severe disease, hospitalization and death.

The findings are a welcome departure from a torrent of worrying new data about Omicron. The variant’s mutations enable it to evade many of the antibodies produced either by vaccination or infection with previous variants. But antibodies are not the only important player in a person’s immune response to the virus.

Continue reading “Vaccines will likely protect against severe disease from Omicron, new lab studies suggest.”

The New York Times, December 15, 2021 (with Rebecca Robbins)

Link

Sanofi, the French pharmaceutical company, said on Wednesday that its once highly anticipated Covid vaccine produced strong immune responses in vaccinated volunteers who received a single dose of the shot as a booster.

The data suggest that the shot, which is still in development and not authorized anywhere in the world, could eventually be used in booster campaigns after it failed to fulfill initial expectations that it would become one of the most important weapons in the fight against the virus. Still, Sanofi has yet to finish a key clinical trial that it said would need to generate results before regulators around the world consider authorizing the shot.

Continue reading “Sanofi’s long-delayed vaccine showed promise as a booster.”

The New York Times, December 14, 2021 (with Rebecca Robbins)

Link

Pfizer announced on Tuesday that its Covid pill was found to stave off severe disease in a key clinical trial and that it is likely to work against the highly mutated Omicron variant of the virus. The results underscore the promise of the treatment, which health officials and doctors are counting on, to ease the burden on hospitals as the United States braces for a mounting fourth wave of the pandemic.

If the Food and Drug Administration authorizes the drug, which could happen within days, then patients might begin receiving it by the end of the year. Although supply will be limited at first, public health experts are hopeful that the pills might curb the worst outcomes from the disease, no matter the variant.

Continue reading “Pfizer’s Covid Pill Works Well, Company Confirms in Final Analysis”